Literature DB >> 26008825

Approaches to demonstration of Ebola virus vaccine efficacy.

Philip R Krause1, Marco Cavaleri2, Gina Coleman3, Marion F Gruber4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26008825     DOI: 10.1016/S1473-3099(15)00027-4

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  5 in total

Review 1.  What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection.

Authors:  Hana Golding; Surender Khurana; Marina Zaitseva
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

2.  Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies.

Authors:  Surender Khurana; Sandra Fuentes; Elizabeth M Coyle; Supriya Ravichandran; Richard T Davey; John H Beigel
Journal:  Nat Med       Date:  2016-10-31       Impact factor: 53.440

3.  Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design.

Authors:  Surender Khurana; Supriya Ravichandran; Megan Hahn; Elizabeth M Coyle; Spencer W Stonier; Samantha E Zak; Jason Kindrachuk; Richard T Davey; John M Dye; Daniel S Chertow
Journal:  Cell Host Microbe       Date:  2020-02-12       Impact factor: 21.023

4.  First vaccine approval under the FDA Animal Rule.

Authors:  David W C Beasley; Trevor L Brasel; Jason E Comer
Journal:  NPJ Vaccines       Date:  2016-08-25       Impact factor: 7.344

Review 5.  The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats.

Authors:  Michael Osterholm; Kristine Moore; Julie Ostrowsky; Kathleen Kimball-Baker; Jeremy Farrar
Journal:  Lancet Infect Dis       Date:  2015-10-30       Impact factor: 25.071

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.